CLINICAL_TRIALS ClinicalTrials.gov record update

Phase 3b, Multicenter, Randomized, Open-Label Study of Risankizumab Compared to Vedolizumab for the Treatment of Adult Subjects With Moderate to Severe Ulcerative Colitis Who Are Naïve to Targeted Therapies

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT06880744
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-06-04T12:58:48.668451+00:00
Published At: 2026-06-03T00:00:00+00:00
Record Updated At: 2026-06-03
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Ulcerative Colitis"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-06-03"
protocolSection.identificationModule.nctId: "NCT06880744"
protocolSection.identificationModule.officialTitle: "Phase 3b, Multicenter, Randomized, Open-Label Study of Risankizumab Compared to Vedolizumab for the Treatment of Adult Subjects With Moderate to Severe Ulcerative Colitis Who Are Na\u00efve to Targeted Therapies"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.